Ignite Creation Date:
2024-10-25 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06537934
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-06-10
Brief Title:
Advanced Mutidimensional and Ultra High Resolution Computed Tomography to Inspect Cardiopulmonary Involvement in Progressive Fibrosing Interstitial Lung Diseases
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Advanced Mutidimensional and Ultra High Resolution Computed Tomography to Inspect Cardiopulmonary Involvement in Progressive Fibrosing Interstitial Lung Diseases
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
AMICI-ILD
Brief Summary:
Interstitial lung diseases ILDs are common chronic disease characterized by high mortality and morbidity also linked to cardiovascular implication Cardiovascular complications occur early in idiopathic pulmonary fibrosis IPF and other ILDs without any symptoms Symptoms are often misinterpreted and diagnosis delayed to irreversible stages of cardiac dysfunction Mechanism of cardiac damage the main cause of mortality are heterogeneous raging from ischemic heart disease acceleration of atherosclerosis to right ventricle dysfunction secondary to pulmonary hypertension So an early recognition and accurate staging are fundamental to avoid disease progression and improve outcomes Currently the non-invasive method of reference for ILD diagnosis and monitoring is high resolution Computed Tomography HRCT which provide information about lung and airway remodeling disease severity and pattern Its application is limited because of the high radiation dose and lack of quantitative early prognosticators additionally it does not provide information on cardiovascular disease and cardiac damage Therefore cardiologic evaluation is mostly performed in late stages when symptoms are evident and the disease is irreversible The identification of a single non-invasive imaging modality able to simultaneously characterize in an accurate and quantitative way the entity of lung and cardiac damage in patients affected by ILD would be useful to improve risk stratification and to guide treatment In order to improve patients diagnosis and clinical management since 2016 in our institution based on a multidisciplinary evaluation including a team made up cardiologist rheumatologist and radiologist we applied a single CT study with contrast agent largely validated in several other clinical setting aimed to combine the assessment of chest and cardiac involvement also in this group of patients However this approach has limited application in clinical practice by the use of old generation CT scanners high radiation exposure limited contrast resolution and by the lack of dedicated postprocessing for the improvement of diagnosis and of the prognostic implication Novel technology as Dual Energy Computed Tomography DECT and Photon Counting CT PCD-CT opened to the possibility to improve ILD characterization using spectral information and ultra-high resolution potentially able to identify precursors of lung and cardiac fibrosis with better image quality at a lower radiation dose In recent studies was shown the possibility to develop a CT protocol able to simultaneously assess coronary artery myocardial scar and interstitial fibrosis and to improve risk stratification in COVID-19 pneumonia deriving quantitative biomarker of systemic comorbidities and cardiovascular risk from chest CT also using artificial intelligence Based on these evidence aim of the study is to develop a CT protocol using advanced technology DECT and PCD-CT able to provide an accurate risk stratification of ILD patients based on a comprehensive evaluation of lung and cardiac damage to quantitatively define the interplay between lung and cardiac remodeling and to identify novel imaging biomarkers useful for prognostication
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None